文献速递心脑血管急症重症综合管理与镇静镇痛

心房颤动患者急性冠脉综合征或PCI后的抗栓治疗

Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation.
PubMed 文献 · N Engl J Med · 2019-03-17
一句话结论房颤合并近期ACS或PCI并计划用P2Y12抑制剂者,含阿哌沙班不含阿司匹林的方案较含维生素K拮抗剂或阿司匹林方案出血更少、住院更少,缺血事件无显著差异。

该国际2×2析因设计试验纳入33个国家4614例房颤合并ACS或PCI并计划服用P2Y12抑制剂的患者,随机接受阿哌沙班或维生素K拮抗剂,以及阿司匹林或安慰剂6个月。主要终点大出血或临床相关非大出血:阿哌沙班组10.5% vs 维生素K拮抗剂组14.7%(HR 0.69,95%CI 0.58-0.81,非劣效和优效P均<0.001);阿司匹林组16.1% vs 安慰剂组9.0%(HR 1.89,95%CI 1.59-2.24,P<0.001)。阿哌沙班组死亡或住院低于维生素K拮抗剂组(23.5% vs 27.4%,HR 0.83,95%CI 0.74-0.93,P=0.002),缺血事件相似;阿司匹林组死亡或住院及缺血事件与安慰剂组相似。

要点

  • 房颤合并ACS或PCI并计划用P2Y12抑制剂者,阿哌沙班较维生素K拮抗剂降低大出血或临床相关非大出血(10.5% vs 14.7%,HR 0.69)。
  • 同人群加用阿司匹林较大出血或临床相关非大出血升高(16.1% vs 9.0%,HR 1.89),死亡或住院及缺血事件与安慰剂相似。
  • 阿哌沙班较维生素K拮抗剂降低死亡或住院(23.5% vs 27.4%,HR 0.83),缺血事件相似。
  • 两随机因素对主要和次要终点无显著交互作用。
  • 含阿哌沙班不含阿司匹林的方案出血和住院更少,缺血事件无显著差异。

适用人群与场景

  • 房颤患者,近期发生急性冠脉综合征或接受过经皮冠状动脉介入治疗(PCI),并计划服用P2Y12抑制剂。

处置流程与药物剂量

  • 随机接受阿哌沙班或维生素K拮抗剂,并随机接受阿司匹林或匹配安慰剂,疗程6个月。

研究设计与关键结果

  • 国际2×2析因设计试验,纳入33个国家4614例房颤合并ACS或PCI并计划服用P2Y12抑制剂的患者。
  • 主要终点大出血或临床相关非大出血:阿哌沙班组10.5% vs 维生素K拮抗剂组14.7%(HR 0.69,95%CI 0.58-0.81,非劣效和优效P均<0.001)。
  • 主要终点大出血或临床相关非大出血:阿司匹林组16.1% vs 安慰剂组9.0%(HR 1.89,95%CI 1.59-2.24,P<0.001)。
  • 死亡或住院:阿哌沙班组23.5% vs 维生素K拮抗剂组27.4%(HR 0.83,95%CI 0.74-0.93,P=0.002)。
  • 缺血事件:阿哌沙班组与维生素K拮抗剂组相似。
  • 死亡或住院及缺血事件:阿司匹林组与安慰剂组相似。
  • 两随机因素对主要或次要终点无显著交互作用。

证据类型、等级与局限

  • 证据类型:国际2×2析因设计随机对照试验(AUGUSTUS,NCT02415400)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 房颤合并近期ACS或PCI并计划用P2Y12抑制剂者,含阿哌沙班不含阿司匹林的抗栓方案较含维生素K拮抗剂、阿司匹林或两者方案出血更少、住院更少,缺血事件无显著差异。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Appropriate antithrombotic regimens for patients with atrial fibrillation who have an acute coronary syndrome or have undergone percutaneous coronary intervention (PCI) are unclear.

METHODS: In an international trial with a two-by-two factorial design, we randomly assigned patients with atrial fibrillation who had an acute coronary syndrome or had undergone PCI and were planning to take a P2Y12 inhibitor to receive apixaban or a vitamin K antagonist and to receive aspirin or matching placebo for 6 months. The primary outcome was major or clinically relevant nonmajor bleeding. Secondary outcomes included death or hospitalization and a composite of ischemic events.

RESULTS: Enrollment included 4614 patients from 33 countries. There were no significant interactions between the two randomization factors on the primary or secondary outcomes. Major or clinically relevant nonmajor bleeding was noted in 10.5% of the patients receiving apixaban, as compared with 14.7% of those receiving a vitamin K antagonist (hazard ratio, 0.69; 95% confidence interval [CI], 0.58 to 0.81; P<0.001 for both noninferiority and superiority), and in 16.1% of the patients receiving aspirin, as compared with 9.0% of those receiving placebo (hazard ratio, 1.89; 95% CI, 1.59 to 2.24; P<0.001). Patients in the apixaban group had a lower incidence of death or hospitalization than those in the vitamin K antagonist group (23.5% vs. 27.4%; hazard ratio, 0.83; 95% CI, 0.74 to 0.93; P = 0.002) and a similar incidence of ischemic events. Patients in the aspirin group had an incidence of death or hospitalization and of ischemic events that was similar to that in the placebo group.

CONCLUSIONS: In patients with atrial fibrillation and a recent acute coronary syndrome or PCI treated with a P2Y12 inhibitor, an antithrombotic regimen that included apixaban, without aspirin, resulted in less bleeding and fewer hospitalizations without significant differences in the incidence of ischemic events than regimens that included a vitamin K antagonist, aspirin, or both. (Funded by Bristol-Myers Squibb and Pfizer; AUGUSTUS ClinicalTrials.gov number, NCT02415400.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Lopes RD, Heizer G, Aronson R, et al. Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. N Engl J Med. 2019. PMID: 30883055. doi:10.1056/NEJMoa1817083

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。